Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons R.A. (Rudolf) de Boer

Publicaties

Challenges in the diagnosis of heart failure with preserved ejection fraction in individuals with obesity

Circulating bone morphogenetic protein 10 as a novel marker of atrial stress and remodelling in heart failure

Micronutrient deficiencies and new-onset atrial fibrillation in a community-based cohort: Data from PREVEND

The Role of Comorbidities and Lifestyle Factors in Disease Progression of Phospholamban Cardiomyopathy

An increase in albuminuria is associated with a higher incidence of malignancies

Association of fibrotic markers with diastolic function after STEMI

Associations of relative fat mass and BMI with all-cause mortality: Confounding effect of muscle mass

Captopril mitigates radiation-induced cardiopulmonary side-effects only if the lung is spared

Captopril mitigates radiation-induced cardiopulmonary side-effects only if the lung is spared

Cardiovascular toxicities of immune therapies for cancer – a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology

Pers/media

ESC-congres 2023 Gesprek van de dag | Hartfalen

FOCUS: praktische overwegingen bij starten van SGLT2-remmers bij hartfalen

De nieuwe ESC-hartfalenrichtlijn 2021 in het kort

Eerste kunsthart in Nederland geplaatst bij 54-jarige man

Dr Rudolf de Boer on SGLT2 Inhibitor Success Across Disease States

Nier- en HF-uitkomsten met SGLT2-remmer in het gehele EF spectrum in HF

Dr Rudolf de Boer Discusses Encouraging Trial Results on SGLT2 Use in HFpEF

Effecten van SGLT2-remmers in vogelvlucht

Margreet Westerhof heeft de noordelijke hartziekte PLN: 'Je leeft met een tijdbom'